Harold Nathan Tan

Harold Nathan Tan

Auto-generated profile, based on publicly available information

Harold Nathan Tan

Department of Investigational Cancer Therapeutics (Phase I Program), University of Texas MD Anderson Cancer Center, Houston

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2025 in Journal of Hematology & Oncology
Verified
Journal Article
Open access
PDF file
HTHarold Nathan Tan
Harold Nathan Tan
MMMarta Ascanio Morcillo
Marta Ascanio Morcillo
JLJuanita Lopez
Juanita Lopez
AMAnna Minchom
Anna Minchom
ASAdam Sharp
Adam Sharp
UBUdai Banerji
Udai Banerji
Antibody–drug conjugates (ADCs) aim to enhance the therapeutic index of cytotoxic agents but can cause unexpected toxicities. This study evaluated adverse events (AEs) from phase 1 trials at The Royal Marsden Drug Development Unit (DDU) over a decade and pivotal phase 2 and 3 trials leading to FDA registration, correlating AEs with ADC components such as target, antibody, linker, payload, and Drug-to-Antibody Ratio (DAR). We performed a retrospective cohort analysis of patients treated with ADCs in phase 1 trials (January 2014 to January 2024) compared to published phase 2–3 trials of FDA-approved ADCs. Univariate and multivariate logistic regression analyzed ADC components and treatment toxicities. One hundred thirty one phase 1 trial patients and 2666 phase 2–3 trial participants were included. High incidences of any-grade treatment-related AEs were observed (89% in phase 1, 93% in phase 2–3), with 58% experiencing grade 3 or higher toxicities in phase 1 and 46% in later phases. Major AEs included fatigue, hematologic toxicities, nausea/vomiting, ocular toxicities, and peripheral neuropathy. Antibody targets were linked to neuropathy, non-cleavable linkers to ocular, pulmonary, and hematologic toxicities, and tubulin-binding payloads to peripheral neuropathy. ADCs with DAR > 4 were associated with higher pulmonary and hematologic AEs. Despite their design to minimize toxicity, ADCs were linked to significant AEs. Specific ADC components may contribute to distinct toxicities, necessitating more robust trial data to inform future ADC design.

8 September 2020 in Journal of Immunotherapy
Verified
Journal Article
Closed access
HTHarold N.C. Tan
Harold N.C. Tan
LCLance I.G. Catedral
Lance I.G. Catedral
MJMichael D. San Juan
Michael D. San Juan
Tumor-infiltrating lymphocytes (TILs) play an important role in mediating treatment response in pancreatic cancer. This meta-analysis investigated the prognostic significance of TIL subsets on overall survival (OS) and disease-free survival (DFS) of patients with pancreatic cancer. Studies were gathered via search of PubMed, Google Scholar, and Cochrane Library databases up to August 1, 2019. Using Review Manager version 5.3.5, pooled hazard ratios and 95% confidence intervals (CIs) were calculated using random or fixed-effects models, depending on the heterogeneity of studies. A total of 11 studies comprising 1760 patients were included in the meta-analysis. Pooled analysis revealed that high CD8+ TILs were associated with improved OS [hazard ratio (HR)=0.59, 95% CI=0.51–0.69, P<0.00001] and DFS (HR=0.60, 95% CI=0.50–0.73, P<0.00001). Similarly, high CD3+ TILs correlated with better OS (HR=0.64, 95% CI=0.54–0.75, P<0.00001) and DFS (HR=0.53, 95% CI=0.31–0.92, P<0.0001). In contrast, high FoxP3+ TILs were associated with worse OS (HR=1.39, 95% CI=1.03–1.88, P=0.03). Finally, high CD4+ TILs showed significant improvement in OS (HR=0.74, 95% CI=0.63–0.86, P=0.0001). TILs are a promising prognostic biomarker in pancreatic cancer. Prospective studies evaluating TILs are recommended as well as the establishment of standards in the assessment of TILs.

1 November 2020 in JCO Global Oncology
Verified
Journal Article
Open access
LCLance Isidore Catedral
Lance Isidore Catedral
HTHarold Nathan Tan
Harold Nathan Tan
AJAlfredo Viray Chua, Jr.
Alfredo Viray Chua, Jr.
DSDanielle Benedict Sacdalan
Danielle Benedict Sacdalan
DSDennis Sacdalan
Dennis Sacdalan
PURPOSE: Several factors affect how medical oncologists in the Philippines use biomarkers in real-world practice. This study describes patterns of biomarker testing for the management of breast, colorectal, and lung cancers among medical oncologists in the Philippines. METHODS: A cross-sectional survey was performed among practicing medical oncologists in the Philippines from November to December 2019. The questionnaire determined the ideal and practical use of biomarkers as perceived by the respondents. Responses were summarized. Associations between biomarker use across select conditions were determined. RESULTS: A total of 127 respondents (38% of medical oncologists in the Philippines) participated in this study. In actual practice, 97% of the respondents requested estrogen receptor/progesterone receptor testing, and 93% requested human epidermal growth factor receptor 2 testing. For colorectal cancer, the respondents would use KRAS and mismatch repair/microsatellite instability, but 59.84% had never used BRAF. For lung cancer, 97.64% of respondents would test for epidermal growth factor receptor ( EGFR), 88.19% would test for PD-L1, 80.31% for anaplastic lymphoma kinase, 58.27% for ROS1, and 33.07% for BRAF. In actual practice, EGFR was the most frequently ordered test (67.72%), while 44.80% of medical oncologists had never used ROS1. The most common reason for testing was adherence to international guidelines (96%). The most commonly cited barrier to biomarker use was patients’ financial constraints (94.49%). Overall, the respondents’ use of biomarkers was not significantly associated with institutional affiliation, the number of patients they saw monthly, and the availability of biomarker tests in their areas of practice. CONCLUSION: Medical oncologists in the Philippines would use biomarkers in treating breast, colorectal, and lung cancers if these were clinically indicated and if cost were not a factor. Financial difficulty experienced by patients was the most commonly cited barrier to biomarker use.

9 February 2022 in BMJ Case Reports
Verified
Journal Article
Closed access
PDF file
HTHarold Nathan Tan
Harold Nathan Tan
LCLance Isidore Garcenila Catedral
Lance Isidore Garcenila Catedral
RJRogelio Nona Velasco Jr.
Rogelio Nona Velasco Jr.
MJMichael San Juan
Michael San Juan
Receptor conversion in breast cancer occurs in up to 32% of patients, resulting in ineffective therapy in the absence of corresponding biomarkers. We report a case of a middle-aged woman who presented with a 2-month history of hoarseness. Laryngoscopy demonstrated right vocal cord paralysis. Whole body positron emission tomography-CT (PET-CT) scan showed a hypermetabolic cervical lymph node, worrisome for metastasis. Biopsy of the cervical lymph node was consistent with metastatic carcinoma of the breast (GATA3 and mammaglobin positive, oestrogen receptor (OR)-positive, progesterone receptor-negative and human epidermal growth factor receptor 2 (HER2)-positive). She underwent targeted therapy with ado-trastuzumab emtansine every 3 weeks. Repeat PET-CT scan after 6 months showed stable disease. Reassessment of receptor status in metastatic breast cancer is encouraged to rule out receptor conversion. There is significant cross-talk between OR and HER2 signalling pathways, leading to treatment resistance. Close collaboration and teamwork among various subspecialties facilitate prompt management of patients with suspected metastatic breast cancer.

12 June 2026 in npj Precision Oncology
Verified
Journal Article
Open access
HTHarold Nathan Tan
Harold Nathan Tan
HLHung Le
Hung Le
KFKhaoula Ben Haj Frej
Khaoula Ben Haj Frej
LKLei Kang
Lei Kang
SCStephane Champiat
Stephane Champiat
EDEcaterina E. Dumbrava
Ecaterina E. Dumbrava
Thymic carcinoma, thymoma, and thymic neuroendocrine tumors are rare malignancies with limited treatment options in advanced stages. Immune checkpoint inhibitors (ICIs) have shown preliminary activity in thymic tumors, although their clinical benefit and toxicity profile remain incompletely defined. We retrospectively analyzed patients with thymic tumors treated with ICIs at MD Anderson Cancer Center from 2010 to 2024. Clinical characteristics, molecular profiles, treatment details, immune-related adverse events (irAEs), and survival outcomes were collected. The primary objective was ICI safety. Secondary endpoints included objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS). Cox regression identified predictors of survival. Forty-two patients were analyzed (median age, 59 years; 55% male), comprising 29 thymic carcinomas, 8 thymomas, and 5 neuroendocrine tumors. ICIs were administered as monotherapy (55%) or combinations (45%), most commonly anti-PD-1 agents (86%). IrAEs occurred in 60% overall and in all patients with thymoma. Grade ≥3 irAEs developed in 19%, including one treatment-related death from pneumonitis. Common irAEs included fatigue, rash, and musculoskeletal symptoms. Notable neuromuscular syndromes included concurrent myasthenia gravis and myocarditis in thymoma. Among 37 RECIST-evaluable patients, ORR was 21%, and DCR was 78%. Median PFS was 6.5 months, and median OS was 9.1 months. Any-grade irAEs were associated with reduced mortality risk (HR, 0.30). TP53 mutations and lung metastases predicted worse OS, whereas CDKN2A alterations correlated with improved OS. ICIs demonstrated preliminary activity in thymic tumors but were associated with substantial toxicity, especially in thymoma. Biomarker-driven patient selection and vigilant irAE monitoring are needed.

30 September 2021
Verified
Journal Article
Open access
PDF file
HTHarold Nathan C. Tan
Harold Nathan C. Tan
MTMaria Belen E Tamayo
Maria Belen E Tamayo
RERegina T. Edusma-Dy
Regina T. Edusma-Dy
FLFrancisco Vicente F. Lopez
Francisco Vicente F. Lopez
Background. Triple-negative breast cancer (TNBC) comprises 15-20% of all breast cancers and is marked by early relapse and poor overall survival. Adjuvant chemotherapy has become the standard of care for these patients albeit to this time there is no consensus on its optimal chemotherapy regimen. This study determined the disease-free-survival (DFS) and overall survival (OS) of patients with stage I-III triple-negative breast cancer given adjuvant chemotherapy in Makati Medical Center from 2000 to 2015. Methods. A single institution (Makati Medical Center), retrospective cohort was conducted involving 157 stage I-III triple-negative breast cancer patients, diagnosed from January 2000 to June 2015, who completed an adjuvant chemotherapy regimen and had at least 3 years of follow up with their medical oncologist. Review of charts of these patients was done, and the demographic, clinical, histopathologic, chemotherapy, recurrence and mortality data were collected and analyzed. The OS and DFS rates were estimated using the Kaplan-Meier method. Results. 107 stage I-III triple-negative breast cancer patients who met eligibility criteria were included in the analysis. The most common chemotherapy regimens were sequential anthracycline-taxane (32 patients, 29.09%) and anthracycline-based regimens (32 patients, 29.09%). The 5-year median OS of TNBC patients given adjuvant chemotherapy was 78.94% (95% CI: 69% to 86%) while the 5-year median DFS of TNBC patients was 71.71% (95% CI: 61.68% – 79.5%). There was no significant association between overall survival or disease-free survival and treatment with a particular chemotherapy regimen. Conclusions. Adjuvant chemotherapy with sequential anthracycline-taxane, concurrent anthracycline-taxane, CMF, anthracycline-based and taxane-based regimens among stage I-III triple-negative breast cancer patients in Makati Medical Center resulted in comparable overall survival and disease-free survival. The use of immune checkpoint inhibitors presents a viable option in TNBC as demonstrated in the Impassion 130 and KEYNOTE 119 trials, and should be further evaluated in the Philippine setting. Keywords: triple-negative breast cancer, adjuvant chemotherapy, overall survival, disease free survival